Impact of Inflammatory Response Modifiers on the Incidence of Hospital-Acquired Infections in Patients with COVID-19
Introduction The study aim was to assess the influence of inflammatory response modifiers, including anti-interleukin-6 (IL-6) biologics and corticosteroids, on the incidence of hospital-acquired infections in patients with coronavirus disease 2019 (COVID-19). Methods Case–control study performed at a university hospital from February 26 to May 26, 2020. Cases were defined as patients with COVID-19 who developed hospital-acquired infections. For each case, two controls were selected among patients without infections. Cases and controls were matched obeying three criteria in a hierarchical sequence: length of hospital stay up until the first infection; comorbidity; and need for Intensive care unit (ICU) admission. Conditional logistic regression analysis was used to estimate the association of exposures with being a case. Results A total of 71 cases and 142 controls were included. Independent predictors for acquiring a hospital infection were chronic liver disease [odds ratio (OR) 16.56, 95% CI 1.87–146.5, p = 0.012], morbid obesity (OR 6.11, 95% CI 1.06–35.4, p = 0.043), current or past smoking (OR 4.15, 95% CI 1.45–11.88, p = 0.008), exposure to hydroxychloroquine (OR 0.2, 95% CI 0.041–1, p = 0.053), and invasive mechanical ventilation (OR 61.5, 95% CI 11.08–341, p ≤ 0.0001). Conclusions Inflammatory response modifiers had no influence on acquisition of nosocomial infections in admitted patients with COVID-19. Hospital-acquired infections primarily occurred in the critically ill and invasive mechanical ventilation was the main exposure conferring risk..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
---|---|
Enthalten in: |
Infectious diseases and therapy - 10(2021), 3 vom: 11. Juni, Seite 1407-1418 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Meira, Fernanda [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
COVID-19 |
---|
Anmerkungen: |
© The Author(s) 2021 |
---|
doi: |
10.1007/s40121-021-00477-9 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2126944328 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | OLC2126944328 | ||
003 | DE-627 | ||
005 | 20240409071155.0 | ||
007 | tu | ||
008 | 230505s2021 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1007/s40121-021-00477-9 |2 doi | |
035 | |a (DE-627)OLC2126944328 | ||
035 | |a (DE-He213)s40121-021-00477-9-p | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
100 | 1 | |a Meira, Fernanda |e verfasserin |4 aut | |
245 | 1 | 0 | |a Impact of Inflammatory Response Modifiers on the Incidence of Hospital-Acquired Infections in Patients with COVID-19 |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a © The Author(s) 2021 | ||
520 | |a Introduction The study aim was to assess the influence of inflammatory response modifiers, including anti-interleukin-6 (IL-6) biologics and corticosteroids, on the incidence of hospital-acquired infections in patients with coronavirus disease 2019 (COVID-19). Methods Case–control study performed at a university hospital from February 26 to May 26, 2020. Cases were defined as patients with COVID-19 who developed hospital-acquired infections. For each case, two controls were selected among patients without infections. Cases and controls were matched obeying three criteria in a hierarchical sequence: length of hospital stay up until the first infection; comorbidity; and need for Intensive care unit (ICU) admission. Conditional logistic regression analysis was used to estimate the association of exposures with being a case. Results A total of 71 cases and 142 controls were included. Independent predictors for acquiring a hospital infection were chronic liver disease [odds ratio (OR) 16.56, 95% CI 1.87–146.5, p = 0.012], morbid obesity (OR 6.11, 95% CI 1.06–35.4, p = 0.043), current or past smoking (OR 4.15, 95% CI 1.45–11.88, p = 0.008), exposure to hydroxychloroquine (OR 0.2, 95% CI 0.041–1, p = 0.053), and invasive mechanical ventilation (OR 61.5, 95% CI 11.08–341, p ≤ 0.0001). Conclusions Inflammatory response modifiers had no influence on acquisition of nosocomial infections in admitted patients with COVID-19. Hospital-acquired infections primarily occurred in the critically ill and invasive mechanical ventilation was the main exposure conferring risk. | ||
650 | 4 | |a COVID-19 | |
650 | 4 | |a Inflammatory response modifiers | |
650 | 4 | |a Nosocomial infections | |
650 | 4 | |a SARS-CoV-2 | |
700 | 1 | |a Moreno-García, Estela |4 aut | |
700 | 1 | |a Linares, Laura |4 aut | |
700 | 1 | |a Macaya, Irene |4 aut | |
700 | 1 | |a Tomé, Adria |4 aut | |
700 | 1 | |a Hernández-Meneses, Marta |4 aut | |
700 | 1 | |a Albiach, Laia |4 aut | |
700 | 1 | |a Morata, Laura |4 aut | |
700 | 1 | |a Letona, Laura |4 aut | |
700 | 1 | |a Bodro, Marta |4 aut | |
700 | 1 | |a Cózar-Llistó, Alberto |4 aut | |
700 | 1 | |a Cardozo, Celia |4 aut | |
700 | 1 | |a Chumbita, Mariana |4 aut | |
700 | 1 | |a Pitart, Cristina |4 aut | |
700 | 1 | |a Ambrosioni, Juan |4 aut | |
700 | 1 | |a Rico, Verónica |4 aut | |
700 | 1 | |a Agüero, Daiana |4 aut | |
700 | 1 | |a Puerta-Alcalde, Pedro |4 aut | |
700 | 1 | |a Garcia-Pouton, Nicole |4 aut | |
700 | 1 | |a Marco, Francesc |4 aut | |
700 | 1 | |a Garcia-Vidal, Carolina |4 aut | |
700 | 1 | |a Soriano, Alex |0 (orcid)0000-0002-9374-0811 |4 aut | |
700 | 1 | |a Martínez, José Antonio |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Infectious diseases and therapy |d Springer Healthcare, 2012 |g 10(2021), 3 vom: 11. Juni, Seite 1407-1418 |h Online-Ressource |w (DE-627)735690766 |w (DE-600)2701611-0 |w (DE-576)378497367 |x 2193-6382 |7 nnns |
773 | 1 | 8 | |g volume:10 |g year:2021 |g number:3 |g day:11 |g month:06 |g pages:1407-1418 |
856 | 4 | 1 | |u https://doi.org/10.1007/s40121-021-00477-9 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2446 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 10 |j 2021 |e 3 |b 11 |c 06 |h 1407-1418 |